{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:40:08Z","timestamp":1790844008223,"version":"4.1.0"},"reference-count":185,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01474","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:12:42Z","timestamp":1530144762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":200,"title":["Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment\u2014A Review From the Melanoma Perspective and Beyond"],"prefix":"10.3389","volume":"9","author":[{"given":"Kristina","family":"Buder-Bakhaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-016-0179-0","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: volume II \u2013 clinical validation and regulatory considerations","volume":"4","author":"Dobbin","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: volume I \u2013 pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B22","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77404","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2217\/imt-2016-0083","article-title":"Use of LDH and autoimmune side effects to predict response to ipilimumab treatment","volume":"8","author":"Dick","year":"2016","journal-title":"Immunotherapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1479-5876-12-116","article-title":"Clinical experience with ipilimumab 3 mg\/kg: real-world efficacy and safety data from an expanded access programme cohort","volume":"12","author":"Ascierto","year":"2014","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-014-1528-9","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.ejca.2015.06.130","article-title":"Personalised medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab","volume":"51","author":"Valpione","year":"2015","journal-title":"Eur J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br J Cancer"},{"key":"B43","first-page":"6303","article-title":"Long-term survival with ipilimumab: experience from a national expanded access program for patients with melanoma","volume":"35","author":"Krajsova","year":"2015","journal-title":"Anticancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1323618","DOI":"10.1080\/2162402X.2017.1323618","article-title":"Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients","volume":"6","author":"Maccalli","year":"2017","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-16-0249","article-title":"Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjd.14155","article-title":"High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma","volume":"174","author":"Zaragoza","year":"2016","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2340\/00015555-2872","article-title":"Blood predictive biomarkers for nivolumab in advanced melanoma","volume":"98","author":"Chasseuil","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16427","article-title":"Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population","author":"Fujisawa","year":"2018","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","volume":"4","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-018-0328-8","article-title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","volume":"6","author":"Subrahmanyam","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype effects cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","article-title":"Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fonc.2014.00110","article-title":"Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels","volume":"4","author":"Leung","year":"2014","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-15-2303","article-title":"Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab","volume":"75","author":"Koguchi","year":"2015","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1158\/2326-6066.CIR-17-0412","article-title":"A serum protein signature associated with outcome after anti-PD-1 therapy in metastatic melanoma","volume":"6","author":"Weber","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1073\/pnas.1719264115","article-title":"Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy","volume":"115","author":"Hong","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/jid.2015.127","article-title":"Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment","volume":"135","author":"Gray","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.neo.2017.08.004","article-title":"Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients","volume":"19","author":"Frankel","year":"2017","journal-title":"Neoplasia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/cam4.1267","article-title":"Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma","volume":"7","author":"Hassel","year":"2018","journal-title":"Cancer Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2014.58.0209","article-title":"C-reactive protein as a marker of melanoma progression","volume":"33","author":"Fang","year":"2015","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0143080","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"103117","DOI":"10.18632\/oncotarget.21602","article-title":"Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer","volume":"8","author":"Oya","year":"2017","journal-title":"Oncotarget"},{"key":"B78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: a cell with many roles in inflammation or several cell types?","volume":"9","author":"Rosales","year":"2018","journal-title":"Front Physiol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the gustave roussy immune score (GRIm-score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-017-0287-5","article-title":"Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy","volume":"5","author":"Jeyakumar","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1684\/ejd.2017.3167","article-title":"A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma","volume":"28","author":"Finon","year":"2018","journal-title":"Eur J Dermatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"254ra128","DOI":"10.1126\/scitranslmed.3008918","article-title":"Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response","volume":"6","author":"Kvistborg","year":"2014","journal-title":"Sci Transl Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"101994","DOI":"10.18632\/oncotarget.22025","article-title":"Expression of PD-1\/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients","volume":"8","author":"Arrieta","year":"2017","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e1002309","DOI":"10.1371\/journal.pmed.1002309","article-title":"Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis","volume":"14","author":"Snyder","year":"2017","journal-title":"PLoS Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ijc.29818","article-title":"Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic malignant melanoma","volume":"138","author":"Wistuba-Hamprecht","year":"2016","journal-title":"Int J Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/eji.201242529","article-title":"The soluble isoform of CTLA-4 as a regulator of T-cell responses","volume":"43","author":"Ward","year":"2013","journal-title":"Eur J Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.11.023","article-title":"High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer","volume":"104","author":"Okuma","year":"2017","journal-title":"Lung Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"97671","DOI":"10.18632\/oncotarget.18311","article-title":"Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"B90","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","article-title":"High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis","volume":"59","author":"Finkelmeier","year":"2016","journal-title":"Eur J Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1074-7613(00)80123-5","article-title":"CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism","volume":"11","author":"Shrikant","year":"1999","journal-title":"Immunity"},{"key":"B92","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B94","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000478893","article-title":"Liquid biopsy: value for melanoma therapy","volume":"40","author":"Buder-Bakhaya","year":"2017","journal-title":"Oncol Res Treat"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3892\/ol.2017.7671","article-title":"High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab","volume":"15","author":"Bao","year":"2018","journal-title":"Oncol Lett"},{"key":"B96","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12885-016-2758-3","article-title":"Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients","volume":"16","author":"Anantharaman","year":"2016","journal-title":"BMC Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/annonc\/mdx206","article-title":"Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma","volume":"28","author":"Strati","year":"2017","journal-title":"Ann Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","volume":"28","author":"Cabel","year":"2017","journal-title":"Ann Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1158\/1078-0432.CCR-13-2906","article-title":"Blood mRNA expression profiling predicts survival in patients treated with tremelimumab","volume":"20","author":"Saenger","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman","year":"2017","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B104","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome effects efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/j.jtho.2016.08.106","article-title":"P2.35: nivolumab vs docetaxel in advanced NSCLC: CheckMate 017\/057 2-Y update and exploratory cytokine profile analysis: track: immunotherapy","volume":"11","author":"Borghaei","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J Transl Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J Clin Invest"},{"key":"B117","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1415938","article-title":"Genetic basis for clinical response to CTLA-4 blockade","volume":"372","author":"Snyder","year":"2015","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B126","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1758834017749748","DOI":"10.1177\/1758834017749748","article-title":"Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients","volume":"10","author":"Karachaliou","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","article-title":"Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study","volume":"42","author":"Sachpekidis","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET\/CT imaging in patients with advanced melanoma","volume":"58","author":"Cho","year":"2017","journal-title":"J Nucl Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","author":"Anwar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B133","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00259-017-3813-2","article-title":"18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start","volume":"45","author":"Seith","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B134","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas","year":"2013","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/gcc.22468","article-title":"Mutation patterns in genes encoding interferon signaling and antigen presentation: a pan-cancer survey with implications for the use of immune checkpoint inhibitors","volume":"56","author":"Budczies","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.3892\/ol.2018.7855","article-title":"Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"key":"B142","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"B143","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"B144","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B145","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"77415","DOI":"10.18632\/oncotarget.20492","article-title":"Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1158\/0008-5472.CAN-16-0170","article-title":"Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses","volume":"76","author":"Colli","year":"2016","journal-title":"Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"key":"B153","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","article-title":"Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade","volume":"5","author":"Nathanson","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B154","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00262-012-1227-3","article-title":"Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab","volume":"61","author":"Shahabi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B155","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"B159","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41379-018-0029-3","article-title":"Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer","volume":"31","author":"Lee","year":"2018","journal-title":"Mod Pathol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total mutation burden in lung cancer and relationship with response to PD-1\/PD-L1 targeted therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/jco.2014.32.15_suppl.3015","article-title":"Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475","volume":"32","author":"Joseph","year":"2014","journal-title":"J Clin Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s00259-014-2848-x","article-title":"Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging","volume":"41","author":"Gilardi","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B167","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by (18)F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B168","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cpet.2014.03.005","article-title":"Proliferation imaging with (1)(8)F-fluorothymidine PET\/computed tomography: physiologic uptake, variants, and pitfalls","volume":"9","author":"Herrmann","year":"2014","journal-title":"PET Clin"},{"key":"B169","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/RLU.0b013e318262c76a","article-title":"Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma","volume":"37","author":"Enslow","year":"2012","journal-title":"Clin Nucl Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"10128","DOI":"10.18632\/oncotarget.24176","article-title":"(18)F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer","volume":"9","author":"Wieder","year":"2018","journal-title":"Oncotarget"},{"key":"B171","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13550-017-0302-3","article-title":"FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study","volume":"7","author":"Mogensen","year":"2017","journal-title":"EJNMMI Res"},{"key":"B172","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fonc.2018.00018","article-title":"Targeted therapy and immunotherapy response assessment with F-18 fluorothymidine positron-emission tomography\/magnetic resonance imaging in melanoma brain metastasis: a pilot study","volume":"8","author":"Nguyen","year":"2018","journal-title":"Front Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00259-016-3494-2","article-title":"The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma","volume":"44","author":"Poulsen","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B174","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2967\/jnumed.116.180075","article-title":"(18)F-FET PET uptake characteristics in patients with newly diagnosed and untreated brain metastasis","volume":"58","author":"Unterrainer","year":"2017","journal-title":"J Nucl Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/0972-3919.130274","article-title":"FLT PET-CT in evaluation of treatment response","volume":"29","author":"Sanghera","year":"2014","journal-title":"Indian J Nucl Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/neuonc\/now154","article-title":"Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases","volume":"18","author":"Kebir","year":"2016","journal-title":"Neuro Oncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.mri.2017.11.008","article-title":"Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: how do permeability and perfusion vary between human tumours?","volume":"46","author":"Little","year":"2018","journal-title":"Magn Reson Imaging"},{"key":"B178","doi-asserted-by":"publisher","first-page":"38513","DOI":"10.18632\/oncotarget.9567","article-title":"Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"B179","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nri3531","article-title":"Tracking immune cells in vivo using magnetic resonance imaging","volume":"13","author":"Ahrens","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1084\/jem.20161950","article-title":"Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells","volume":"214","author":"Rashidian","year":"2017","journal-title":"J Exp Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","article-title":"An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy","volume":"76","author":"Tavare","year":"2016","journal-title":"Cancer Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11307-017-1060-3","article-title":"Development of novel ImmunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model","volume":"19","author":"Natarajan","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1021\/acs.bioconjchem.6b00348","article-title":"PD-L1 detection in tumors using [(64)Cu]atezolizumab with PET","volume":"27","author":"Lesniak","year":"2016","journal-title":"Bioconjug Chem"},{"key":"B184","doi-asserted-by":"publisher","first-page":"e1329071","DOI":"10.1080\/2162402X.2017.1329071","article-title":"Preclinical immunoPET\/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma","volume":"6","author":"Kikuchi","year":"2017","journal-title":"Oncoimmunology"},{"key":"B185","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1021\/acs.bioconjchem.7b00631","article-title":"Imaging PD-L1 expression with ImmunoPET","volume":"29","author":"Truillet","year":"2018","journal-title":"Bioconjug Chem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01474\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:12:47Z","timestamp":1530144767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01474\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":185,"alternative-id":["10.3389\/fimmu.2018.01474"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01474","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"article-number":"1474"}}